<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Physiol Rev</journal-id>
<journal-id journal-id-type="iso-abbrev">Physiol. Rev</journal-id>
<journal-id journal-id-type="pmc">physrev</journal-id>
<journal-id journal-id-type="publisher-id">Physiol Rev</journal-id>
<journal-id journal-id-type="publisher-id">PHYSREV</journal-id>
<journal-title-group>
<journal-title>Physiological Reviews</journal-title>
</journal-title-group>
<issn pub-type="ppub">0031-9333</issn>
<issn pub-type="epub">1522-1210</issn>
<publisher>
<publisher-name>American Physiological Society</publisher-name>
<publisher-loc>Bethesda, MD</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30280653</article-id>
<article-id pub-id-type="pmc">6335099</article-id>
<article-id pub-id-type="publisher-id">PRV-00050-2017</article-id>
<article-id pub-id-type="publisher-manuscript">PRV-00050-2017</article-id>
<article-id pub-id-type="doi">10.1152/physrev.00050.2017</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Blood-Brain Barrier: From Physiology to Disease and Back</article-title>
<alt-title alt-title-type="left-running-head">SWEENEY ET AL.</alt-title>
<alt-title alt-title-type="right-running-head">BLOOD-BRAIN BARRIER: PHYSIOLOGY AND PATHOPHYSIOLOGY</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Sweeney</surname>
<given-names>Melanie D.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhao</surname>
<given-names>Zhen</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Montagne</surname>
<given-names>Axel</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nelson</surname>
<given-names>Amy R.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zlokovic</surname>
<given-names>Berislav V.</given-names>
</name>
</contrib>
<aff id="aff1">Zilkha Neurogenetic Institute, Keck School of Medicine, <institution>University of Southern California</institution>, <addr-line>Los Angeles, California</addr-line>; and Department of Physiology and Neuroscience, Keck School of Medicine, <institution>University of Southern California</institution>, <addr-line>Los Angeles, California</addr-line></aff>
</contrib-group>
<pub-date pub-type="ppub">
<day>1</day>
<month>1</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>3</day>
<month>10</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>1</day>
<month>1</month>
<year>2020</year>
</pub-date>
<!-- PMC Release delay is 12 months and
						0 days and was based on the <pub-date
						pub-type="ppub"/>. -->
<volume>99</volume>
<issue>1</issue>
<fpage>21</fpage>
<lpage>78</lpage>
<history>
<date date-type="received">
<day>2</day>
<month>11</month>
<year>2017</year>
</date>
<date date-type="rev-recd">
<day>17</day>
<month>4</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>17</day>
<month>4</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2019 the American Physiological Society</copyright-statement>
<copyright-year>2019</copyright-year>
<copyright-holder>American Physiological Society</copyright-holder>
</permissions>
<self-uri content-type="pdf" xlink:href="physrev.00050.2017.pdf"></self-uri>
<abstract>
<p>The blood-brain barrier (BBB) prevents neurotoxic plasma components, blood cells, and pathogens from entering the brain. At the same time, the BBB regulates transport of molecules into and out of the central nervous system (CNS), which maintains tightly controlled chemical composition of the neuronal milieu that is required for proper neuronal functioning. In this review, we first examine molecular and cellular mechanisms underlying the establishment of the BBB. Then, we focus on BBB transport physiology, endothelial and pericyte transporters, and perivascular and paravascular transport. Next, we discuss rare human monogenic neurological disorders with the primary genetic defect in BBB-associated cells demonstrating the link between BBB breakdown and neurodegeneration. Then, we review the effects of genes underlying inheritance and/or increased susceptibility for Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease, and amyotrophic lateral sclerosis (ALS) on BBB in relation to other pathologies and neurological deficits. We next examine how BBB dysfunction relates to neurological deficits and other pathologies in the majority of sporadic AD, PD, and ALS cases, multiple sclerosis, other neurodegenerative disorders, and acute CNS disorders such as stroke, traumatic brain injury, spinal cord injury, and epilepsy. Lastly, we discuss BBB-based therapeutic opportunities. We conclude with lessons learned and future directions, with emphasis on technological advances to investigate the BBB functions in the living human brain, and at the molecular and cellular level, and address key unanswered questions.</p>
</abstract>
<funding-group>
<award-group id="award1">
<funding-source>
<named-content content-type="funder-name">HHS | National Institutes of Health (NIH)</named-content>
<named-content content-type="funder-identifier">10.13039/100000002</named-content>
</funding-source>
<award-id>R01AG023084</award-id>
<award-id>R01NS090904</award-id>
<award-id>R01AG039452</award-id>
<award-id>5P01AG052350</award-id>
<award-id>R01NS100459</award-id>
<award-id>R01NS034467</award-id>
</award-group>
<award-group id="award2">
<funding-source>
<named-content content-type="funder-name">Cure Alzheimer's Fund (CAF)</named-content>
<named-content content-type="funder-identifier">10.13039/100007625</named-content>
</funding-source>
</award-group>
<award-group id="award3">
<funding-source>
<named-content content-type="funder-name">Alzheimer's Association</named-content>
<named-content content-type="funder-identifier">10.13039/100000957</named-content>
</funding-source>
<award-id>509279</award-id>
</award-group>
<award-group id="award4">
<funding-source>
<named-content content-type="funder-name">Fondation Leducq</named-content>
<named-content content-type="funder-identifier">10.13039/501100001674</named-content>
</funding-source>
<award-id>16 CVD 05</award-id>
</award-group>
</funding-group>
</article-meta>
</front>
</article>
</pmc-articleset>